DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

Information source: Canadian Network for Observational Drug Effect Studies, CNODES
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Depression; Acute Kidney Injury

Intervention: Duloxetine (Drug); Venlafaxine (Drug); Desvenlafaxine (Drug); Citalopram (Drug); Escitalopram (Drug); Fluoxetine (Drug); Fluvoxamine (Drug); Paroxetine (Drug); Sertraline (Drug)

Phase: N/A

Status: Completed

Sponsored by: Canadian Network for Observational Drug Effect Studies, CNODES

Official(s) and/or principal investigator(s):
Pierre Ernst, MD, MSc, Principal Investigator, Affiliation: Lady Davis Institute for Medical Research, Jewish General Hospital - McGill University

Summary

The purpose of this study is to determine if there is an excess risk of acute kidney injury (AKI) with Serotonin-norepinephrine reuptake inhibitors (SNRIs) as compared to Selective serotonin reuptake inhibitors (SSRIs), two classes of medication used for the treatment of depression.

Clinical Details

Official title: Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Acute Kidney Injury (AKI)

Detailed description: We plan to conduct retrospective population-based cohort studies within eight administrative databases from Canada, the United States, and the United Kingdom. Within each cohort, a nested case-control analysis will be performed to estimate incidence rate ratios (RR) of AKI associated with SNRIs compared to SSRIs using conditional logistic regression, with adjustment for high-dimensional propensity scores at baseline. The overall effect across sites will then be estimated using meta-analytic methods.

Eligibility

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- A first prescription of an antidepressant of the SNRI or SSRI class of any dose

between January 1, 1997 and March 31, 2010. Exclusion Criteria:

- They were <12 years old at the time of cohort entry.

- They had less than 1 year of information in the database prior to the date of cohort

entry.

- They had a prescription of an SNRI or SSRI in the year before the date of cohort

entry.

- They had a prescription for both an SNRI and an SSRI on the day of cohort entry.

- They had a history of chronic kidney disease (including kidney transplantation and

dialysis) or AKI in the year preceding cohort entry.

- The subject was previously included in the cohort.

Locations and Contacts

Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec H3T1E2, Canada
Additional Information

This organization's website describing general functions, other CNODES projects, and investigator profiles.

Starting date: June 2013
Last updated: July 13, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017